Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07190794 · ClinicalTrials.gov registry record
RESCUE: Discontinuation of GLP-1
A clinical trial of Obesity, sponsored by Boston Scientific Corporation.
- Recruiting
- Registry status
- 150
- Enrollment target
- 3
- Study locations
NCT07190794: Recruiting study of Obesity, sponsored by Boston Scientific Corporation.
NCT07190794 is a study of Obesity that is actively recruiting participants, run by Boston Scientific Corporation. The registered enrollment target is 150 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (82% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07190794, a study of Obesity, is actively recruiting participants, sponsored by Boston Scientific Corporation.
- RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study is designed to compare weight loss outcomes and safety of ESG versus lifestyle modification in patients with obesity who discontinued GLP-1 therapy due to intolerance or suboptimal weight loss.
Primary Outcome
The study will measure the percentage of total body weight loss for a period of one year from baseline.
Conditions Studied
Interventions
- BEHAVIORAL Lifestyle Modification
- DEVICE OverStitch™ or OverStitch NXT™
Study Locations (3)
Florida
- Bariendo - Miami
Massachusetts
- Brigham & Women's Hospital - Boston
West Virginia
- West Virginia University - Morgantown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-12-17 |
| Est. Completion | 2026-06 |
What NCT07190794 shows while recruiting
NCT07190794 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Lifestyle Modification is the first listed.
NCT07190794 reports a single indexed study location in Florida, Massachusetts, West Virginia.
Frequently Asked Questions
What is clinical trial NCT07190794 about?
NCT07190794 is a clinical study titled "RESCUE: Discontinuation of GLP-1". This study is designed to compare weight loss outcomes and safety of ESG versus lifestyle modification in patients with obesity who discontinued GLP-1 therapy due to intolerance or suboptimal weight loss.
What is the current status of trial NCT07190794?
This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2025-12-17. Estimated completion is 2026-06.
What conditions does trial NCT07190794 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT07190794?
The interventions under investigation include: Lifestyle Modification (BEHAVIORAL), OverStitch™ or OverStitch NXT™ (DEVICE).
Who is sponsoring clinical trial NCT07190794?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07190794 being conducted?
This trial has 3 study locations across Florida, Massachusetts, West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07190794's enrollment target sits among peer trials
150 370th of 1053 higher than 668 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Hip Flexion Feedback System for Exercise Monitoring in Individuals With Osteoarthritis and Obesity
RECRUITING · Phase 1
-
Metabolic Adaptations to Weight Loss With and Without Exercise
RECRUITING · NA
-
Testing an Integrated PTSD and Weight Management Intervention: A Hybrid Type 1 Trial
RECRUITING · NA
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Tai Chi as a Novel Strategy to Increase Physical Activity Among Adults Pursuing Metabolic and Bariatric Surgery
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI